Recent studies have suggested that circulating tumor DNA (ctDNA) testing has prognostic value in colorectal cancer, but researchers maintain that additional studies are needed to confirm whether and how ctDNA testing should be used in practice.
A study published in Nature Medicine showed that ctDNA testing can identify patients with colorectal cancer who are at high risk of relapse after surgery and can benefit from adjuvant chemotherapy.